Organized by the Spanish Society of Immunology (SEI)
Thursday, September 29th (9h30-11h00)
Room B

Sponsored by:

Organized by:

When the journal Science named Cancer Immunotherapy as "breakthrough of the year 2013" it did nothing but to confirm and sanction a reality that already existed. Less than three years after this distinction we are witnessing an explosion of new therapeutic antibodies and cutting edge methods focused on increasing the success of cell-based therapy. In this symposium we will review how targeting an inhibitory receptor has a relevant impact in the efficacy of therapeutic antibodies. In addition, we will discuss the current thinking and future directions of the Chimeric Antigen Receptor (CAR) T-cell programme for cancer treatment that is being implemented in the University College London; how to identify and expand T cells from blood that are antigen-specific for tumor cells and their use in immunotherapy; and finally, the present and future of a class of innate lymphocytes, termed natural killer (NK) cells, in adoptive cell therapy for cancer treatment.


  • África González Fernández: President, SPANISH SOCIETY OF IMMUNOLOGY (SEI) / Director, BiOMEDICAL RESEARCH CENTER (CINBIO) & Professor in Immunology, UNIVERSITY OF VIGO (Spain). 


  • Mark S. Cragg:  Professor in Immunotherapy, Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, UNIVERSITY OF SOUTHAMPTON-SOUTHAMPTON GENERAL HOSPITAL (United Kingdom). “IIB or not IIB: Contrasting roles of the inhibitory FcyRIIB in regulating different classes of antibody immunotherapy”. 
  • Claire Roddie:  Clinician scientist, Research Department of Haematology, Cancer Institute, Faculty of Medical Sciences, UNIVERSITY COLLEGE OF LONDON (United Kingdom).  CAR T-cell therapy for haematological malignancy”. 
  • Alena Gros: Principal Investigator, Tumour Immunology and Immunotherapy Group, VALL d’HEBRON INSTITUTE OF ONCOLOGY - VHIO (Spain). Identification and isolation of neoantigen-specific lymphocytes in peripheral blood of cancer patients”. 
  • Francisco Borrego:  Ikerbasque Research Professor, Immunopathology Group, BIOCRUCES HEALTH RESEARCH INSTITUTE OF BARAKALDO (Spain).  “NK cell-based cancer Immunotherapy” 
  • Julio Castro: CEO, PALOBIOFARMA (Spain). “Targeting adenosine modulation in the tumor microenvironment: A novel approach in cancer immunotherapy”